Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A PHASE 2 STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR+, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER
Beckwith, H. C. (PI)
9/25/24 → 9/24/35
Project: Research project
-
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734
Beckwith, H. C. (PI)
6/10/24 → 6/9/35
Project: Research project
-
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
Beckwith, H. C. (PI)
10/6/23 → 11/30/25
Project: Research project
-
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
Hensley, M., Lengfeld, J., Stoesz, S., Edwards, M., Pass, F., Hirst, G. L., Brown-Swigart, L., van ‘t Veer, L., Esserman, L. J., Beckwith, H. & Yee, D., 2025, In: Frontiers in Oncology. 15, 1605120.Research output: Contribution to journal › Article › peer-review
Open Access -
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
I-SPY2 Investigators, Jun 1 2025, In: JCO Precision Oncology. 9, e2400776.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Khoury, K., Meisel, J. L., Yau, C., Rugo, H. S., Nanda, R., Davidian, M., Tsiatis, B., Chien, A. J., Wallace, A. M., Arora, M., Rozenblit, M., Hershman, D. L., Zimmer, A., Clark, A. S., Beckwith, H., Elias, A. D., Stringer-Reasor, E., Boughey, J. C., Nangia, C. & Vaklavas, C. & 37 others, , Dec 2024, In: Nature Medicine. 30, 12, p. 3728-3736 9 p., 63.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Shatsky, R. A., Trivedi, M. S., Yau, C., Nanda, R., Rugo, H. S., Davidian, M., Tsiatis, B., Wallace, A. M., Chien, A. J., Stringer-Reasor, E., Boughey, J. C., Omene, C., Rozenblit, M., Kalinsky, K., Elias, A. D., Vaklavas, C., Beckwith, H., Williams, N., Arora, M. & Nangia, C. & 40 others, , Dec 2024, In: Nature Medicine. 30, 12, p. 3737-3747 11 p., 63.Research output: Contribution to journal › Article › peer-review
Open Access20 Scopus citations -
Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time
Shaaban, A., Petersen, A., Beckwith, H., Florea, N., Potter, D. A., Yee, D., Vogel, R. I., Duprez, D. & Blaes, A. H., Dec 2024, In: Cardio-Oncology. 10, 1, 27.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations
Datasets
-
COVID-19 Concerns among Physicians who treat cancer survey in the United States, Cross-sectional study March/April 2020
Vogel, R. I., Thomaier, L., Lou, E., Teoh, D. G., Jewett, P. I., Beckwith, H. C., Parsons, H. M., Yuan, J., Blaes, A. H. & Hui, J., Data Repository for the University of Minnesota, 2020
DOI: 10.13020/bmsy-hb61, http://hdl.handle.net/11299/216451
Dataset